Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials.

Blood (2012) 120 (21): 3165.

https://doi.org/10.1182/blood.V120.21.3165.3165

Published: 2012

Journal Articles

Microfluidic Platform Enabling Primary Multiple Myeloma Mono- and Cis -Co-Culture Analysis

Pak Chorom, BA, Edmond WK Young, PhD, Natalie Callander, MD, David J Beebe, PhD, Shigeki Miyamoto, PhD

Blood (2012) 120 (21): 1830.

https://doi.org/10.1182/blood.V120.21.1830.1830

Published: 2012

Journal Articles

A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation

Christof Scheid, MD, PhD, Donna Reece, Meral Beksac, MD, Andrew Spencer, MD, Natalie Callander, MD, Pieter Sonneveld, MD, Ghulam Kalimi, PhD, Can Cai, Michael Shi, MD, PhD, Jeffrey W. Scott, A. Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 4055.

https://doi.org/10.1182/blood.V120.21.4055.4055

Published: 2012

Journal Articles

Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity

Shaji K. Kumar, MD, Betsy R. LaPlant, Wee Joo Chng, MD, PhD, Jeffrey A. Zonder, MD, Natalie Callander, MD, Vivek Roy, M.D., Briant Furth, Charles Erlichman, MD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 76.

https://doi.org/10.1182/blood.V120.21.76.76

Published: 2012

Journal Articles

Molecular Pathways That Determine the Activation State of Macrophages within the Myeloma Niche

Chelsea Hope, Ellen Hebron, Jaehyup Kim, MD, Jeff Jensen, Claire Flanagan, Neehar Bhatia, Catherine Leith, MBBChir, Ioanna Maroulakou, PhD, Constantine S. Mitsiades, MD, PhD, Shigeki Miyamoto, PhD, Natalie Callander, MD, Peiman Hematti, MD, Fotis Asimakopoulos, MBBChir, PhD

Blood (2012) 120 (21): 443.

https://doi.org/10.1182/blood.V120.21.443.443

Published: 2012

Journal Articles

Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma

Andrew T Humbert, Rachel Cook, MS, MD, Thomas McFarland, Ronald Go, MD, Stephanie Markovina, MD, Shigeki Miyamoto, PhD, Eliot C. Williams, MD, PhD, Fotios Asimakopoulos, MBBChir, PhD, Jill Kolesar, PhD, Michael A. Thompson, MD, PhD, Kyungmann Kim, Natalie Callander, MD

Blood (2012) 120 (21): 5041.

https://doi.org/10.1182/blood.V120.21.5041.5041

Published: 2012

Journal Articles

Optical Mapping of the Myeloma Cancer Genome to Elucidate Mechanisms of Acquired Resistance to Proteasome Inhibitors.

Aditya Gupta, Jaehyup Kim, MD, Chelsea Hope, Jeff Jensen, Natalie Callander, MD, Peiman Hematti, MD, Emery H Bresnick, PhD, David C Schwartz, PhD, Fotis Asimakopoulos, MBBChir, PhD

Blood (2012) 120 (21): 2444.

https://doi.org/10.1182/blood.V120.21.2444.2444

Published: 2012

Journal Articles

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Martha Raschko, MD, Stephanie Markovina, Shigeki Miyamoto, PhD, Walter Longo, MD, Eliot Williams, MD, Thomas McFarland, MD, Jae Werndli, Elisabeth Wagner, Mark Juckett, MD, Natalie Callander, MD

Blood (2007) 110 (11): 1173.

https://doi.org/10.1182/blood.V110.11.1173.1173

Published: 2007

Journal Articles

A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

S. Vincent Rajkumar, MD, Susanna Jacobus, MS, Natalie Callander, MD, Rafael Fonseca, MD, David Vesole, MD, PhD, Michael Williams, MD, Rafat Abonour, MD, David Siegel, MD, Philip Greipp, MD

Blood (2007) 110 (11): 74.

https://doi.org/10.1182/blood.V110.11.74.74

Published: 2007

Journal Articles

A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

S. Vincent Rajkumar, MD, Susanna Jacobus, MS, Natalie Callander, MD, Rafael Fonseca, MD, David Vesole, MD, Philip Greipp, MD

Blood (2006) 108 (11): 799.

https://doi.org/10.1182/blood.V108.11.799.799

Published: 2006

Journal Articles

A Phase II Study of PS-341 for Patients with High Risk, Newly Diagnosed Multiple Myeloma: A Trial of the Eastern Cooperative Oncology Group (E2A02).

Angela Dispenzieri, MD, Emily Blood, MS, David Vesole, MD, Rafael Fonseca, MD, Natalie Callander, MD, Philip R. Greipp, MD

Blood (2005) 106 (11): 2546.

https://doi.org/10.1182/blood.V106.11.2546.2546

Published: 2005

Journal Articles

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Azra Raza, MD, Natalie Callander, MD, Leonel Ochoa, MD, Lawrence Piro, MD, Peter Emanuel, MD, Susan Guba, MD, Gabriel Shapiro, MD, Stephanie Williams, MD, Howard Burris, III, MD, Stefan Faderl, MD, Zeev Estrov, MD, Peter Curtain, MD, Richard Larson, MD, Shelby Young, RN, Gail L. Brown, MD

Blood (2005) 106 (11): 2520.

https://doi.org/10.1182/blood.V106.11.2520.2520

Published: 2005

Journal Articles

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Natalie Callander, MD, Jose L. Ochoa-Bayona, MD, Lawrence Piro, MD, Susan Guba, MD, Gabriel Shapiro, MD, Stephanie Williams, MD, Ira Oliff, MD, Howard Burris, III, MD, Anneliese Jameson, Kiran Patel, Gail L. Brown, MD, Stefan Faderl, MD, Zeev Estrov, MD, Peter Emanuel, MD

Blood (2004) 104 (11): 1428.

https://doi.org/10.1182/blood.V104.11.1428.1428

Published: 2004

Journal Articles

Incidence of Clostridium Difficile -Induced Diarrhea in Patients Treated with High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma and Multiple Myeloma.

Jorge I. Arango, MD, Cesar O. Freytes, MD, Deanna L. Schneider, RN, Alejandro Restrepo, MD, Marcos I. Restrepo, MD, Patrick Bradshaw, MS, Natalie Callander, MD, Leonel Ochoa, MD

Blood (2004) 104 (11): 5059.

https://doi.org/10.1182/blood.V104.11.5059.5059

Published: 2004

Journal Articles

.

Peter Dean Emanuel, MD, Zhuo Wang, PhD, Danying Cai, PhD, Mary R. Stofega, PhD, James G. Keck, PhD, Zeev Estrov, MD, Gail L. Brown, MD, Jose L. Ochoa-Bayona, MD, Natalie Callander, MD

Blood (2004) 104 (11): 2372.

https://doi.org/10.1182/blood.V104.11.2372.2372

Published: 2004

Journal Articles

Valganciclovir for the Early Prophylaxis of Cytomegalovirus (CMV) Infection after Allogeneic Stem Cell Transplantation.

Carlos Bachier, MD, Paul Shaughnessy, MD, Donna Wall, MD, Michael Grimley, MD, George Carrum, MD, Cesar Freytes, MD, Natalie Callander, MD, Tracey Walsh, PharmD, C. Fred LeMaistre, MD

Blood (2004) 104 (11): 5074.

https://doi.org/10.1182/blood.V104.11.5074.5074

Published: 2004

Journal Articles

Efficacy of Fluconazole Prophylaxis for Autologous Peripheral Blood Stem Cell Transplantation: Results of a Prospective, Randomized, Controlled, Multicenter, Open Label Study.

Tracey L. Walsh, PharmD, Carlos Bachier, MD, Paul Shaughnessy, MD, Cesar O. Freytes, MD, Natalie Callander, MD, C. Fred LeMaistre, MD, Michael Grimley, MD, Patrick Bradshaw, MS

Blood (2004) 104 (11): 5096.

https://doi.org/10.1182/blood.V104.11.5096.5096

Published: 2004

NARROW

Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials.

Microfluidic Platform Enabling Primary Multiple Myeloma Mono- and Cis -Co-Culture Analysis

A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation

Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity

Molecular Pathways That Determine the Activation State of Macrophages within the Myeloma Niche

Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma

Optical Mapping of the Myeloma Cancer Genome to Elucidate Mechanisms of Acquired Resistance to Proteasome Inhibitors.

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

A Phase II Study of PS-341 for Patients with High Risk, Newly Diagnosed Multiple Myeloma: A Trial of the Eastern Cooperative Oncology Group (E2A02).

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Incidence of Clostridium Difficile -Induced Diarrhea in Patients Treated with High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma and Multiple Myeloma.

.

Valganciclovir for the Early Prophylaxis of Cytomegalovirus (CMV) Infection after Allogeneic Stem Cell Transplantation.

Efficacy of Fluconazole Prophylaxis for Autologous Peripheral Blood Stem Cell Transplantation: Results of a Prospective, Randomized, Controlled, Multicenter, Open Label Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only